TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18026625

Group type: EXPERIMENTAL
Intervention: Group 1: Vaccine stored within the cold chain and administered in township hospitals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group 2: Vaccine stored out of the cold chain in villages and administered by village-based health workers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group 3: Same strategy as group 2, but vaccine packaged in a prefilled injection device
Number of subjects: 0
Study: 16051334

Group type: EXPERIMENTAL
Intervention: Paclitaxel combined with fixed doses of carboplatin
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Age <52 years
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Age 53-62 years
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Age >=63 years
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Stage III
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Stage IV
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Serous histotype
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Clear cell histotype
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Endometrioid histotype
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Mucinous histotype
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Residual tumour <= 1 cm after surgery
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Residual tumour > 1 cm after surgery
Number of subjects: 232
Study: 11585083

Group type: EXPERIMENTAL
Intervention: 200 microg salbutamol
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 9700123

Group type: EXPERIMENTAL
Intervention: Antithrombin (AT) therapy
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 7923999

Group type: EXPERIMENTAL
Intervention: Lactulose (1 g/100 kcals to a maximum of 28 g/d)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no lactulose)
Number of subjects: 12
Study: 2645313

Group type: EXPERIMENTAL
Intervention: Synthetic GnRH (7.5, 25, 75, and 250 ng/kg) iv at 2-h intervals after long term pulsatile GnRH administration
Number of subjects: 18

Group type: COMPARATOR
Intervention: Endogenous GnRH-stimulated LH peaks in normal men
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Synthetic GnRH (various doses)
Number of subjects: 18
Study: 1067728

Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum (4.5 gums/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sucrose chewing gum (4.0 gums/day)
Number of subjects: 100
Study: 31806260

Group type: EXPERIMENTAL
Intervention: CPR
Number of subjects: 114

Group type: COMPARATOR
Intervention: Vascular access team presence
Number of subjects: 114

Group type: COMPARATOR
Intervention: Caregiver presence
Number of subjects: 114

Group type: COMPARATOR
Intervention: Peripheral intravenous access
Number of subjects: 114
Study: 31587287

Group type: EXPERIMENTAL
Intervention: PRT-treated PLTs
Number of subjects: 132

Group type: COMPARATOR
Intervention: Standard PLTs
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Riboflavin and UV light-treated PLTs
Number of subjects: 132
Study: 28100482

Group type: EXPERIMENTAL
Intervention: Subtenon injection of 0.1 mL of 0.01% MMC
Number of subjects: 80

Group type: COMPARATOR
Intervention: MMC-soaked sponges (0.02%)
Number of subjects: 80
Study: 25904366

Group type: EXPERIMENTAL
Intervention: Active promotion with a multifaceted and repeated intervention (reminders, audit feedback, targeting local opinion leaders)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Simple information on guideline availability
Number of subjects: 306
Study: 23445918

Group type: EXPERIMENTAL
Intervention: Cortical volumetric bone density (vBMD) measurement at anterior region
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cortical volumetric bone density (vBMD) measurement at endocortical region
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Variability in cortical vBMD
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Difference between anterior and posterior regions
Number of subjects: 80
Study: 21393433

Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 8021

Group type: COMPARATOR
Intervention: Placebo plus aspirin
Number of subjects: 8021
Study: 19060721

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 17032001

Group type: EXPERIMENTAL
Intervention: High-L spinach ('Spinner')
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low-L spinach ('Springer')
Number of subjects: 20
Study: 15483415

Group type: EXPERIMENTAL
Intervention: Anti-TNF therapy (neutralizing antibody directed against tumor necrosis factor) at varying doses for 6, 24, or 48 hours
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Control group (no anti-TNF therapy)
Number of subjects: 1000
Study: 10675115

Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional (open) Nissen fundoplication
Number of subjects: 12
Study: 9084461

Group type: EXPERIMENTAL
Intervention: rhPTH(1-84) at doses 0.02 to 5.0 micrograms.kg-1
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: rhPTH(1-84) at doses > 2.5 micrograms.kg-1
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: rhPTH(1-84) at doses > or = 1.5 micrograms.kg-1
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: rhPTH(1-84)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 7934973

Group type: EXPERIMENTAL
Intervention: Propranolol 240 mg/d
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 3278068

Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg suppositories twice daily
Number of subjects: 83

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) 1000 mg effervescent tablets three times daily
Number of subjects: 83
Study: 31185775

Group type: EXPERIMENTAL
Intervention: Virtual kayak paddling (VKP) exercise for 60 min twice a week for 6 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group performing home exercises
Number of subjects: 60
Study: 29292274

Group type: EXPERIMENTAL
Intervention: SpotOn monitoring system
Number of subjects: 38
Study: 26960042

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation for 1 month
Number of subjects: 65

Group type: COMPARATOR
Intervention: No cardiac rehabilitation (control group)
Number of subjects: 65
Study: 24427287

Group type: EXPERIMENTAL
Intervention: Thrombin-reactive phages selected using biotinylated anti-thrombin antibodies and streptavidin-coated magnetic beads.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mock selection of the same library without thrombin.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: API M358R randomized at residues 352-356 (P7-P3).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Most active candidates from the sixth round of screening containing DITMA and AAFVS at P7-P3.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deep sequencing using the Ion Torrent platform.
Number of subjects: 0
Study: 22409563

Group type: EXPERIMENTAL
Intervention: Patients with hypotony at baseline
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Patients with uveitis ≥5 years duration
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Patients with a history of ocular surgery (vitrectomy)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Patients with older age of uveitis onset (>51 years)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Caucasian patients
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Hypotonous eyes
Number of subjects: 240
Study: 18801582

Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (TD)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no TD)
Number of subjects: 18
Study: 17617557

Group type: EXPERIMENTAL
Intervention: 20 G Optiva i.v. plastic cannula
Number of subjects: 120

Group type: COMPARATOR
Intervention: Stevens' sub-Tenon's metal cannula
Number of subjects: 120
Study: 15196524

Group type: EXPERIMENTAL
Intervention: Walker
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cane
Number of subjects: 10

Group type: COMPARATOR
Intervention: No assistive device (hands free or holding an object)
Number of subjects: 10
Study: 12905675

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9698949

Group type: EXPERIMENTAL
Intervention: Single-injection spinal anaesthesia (SA)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Epidural anaesthesia (EA)
Number of subjects: 224
Study: 10144552

Group type: EXPERIMENTAL
Intervention: Training program that includes information about self-help groups
Number of subjects: 26

Group type: COMPARATOR
Intervention: Training program that does not address self-help groups
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Experiential component of the training
Number of subjects: 26
Study: 2145957

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 751811

Group type: EXPERIMENTAL
Intervention: Problem-Solving intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: Insight-oriented treatment
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Problem-Solving therapy
Number of subjects: 20
Study: 7034929

Group type: EXPERIMENTAL
Intervention: MTX 5 g/m2
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: MTX 500 mg/m2
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: MTX 50 mg/m2
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: High-dose MTX
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: MTX (all doses)
Number of subjects: 58
Study: 31790639

Group type: EXPERIMENTAL
Intervention: Multimodal Rehabilitation Program (MMRP) with mHealth app
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional rehabilitation program
Number of subjects: 41
Study: 31268828

Group type: EXPERIMENTAL
Intervention: Variable RT (VAR; modulating exercise load, volume, contraction type, and interset rest interval)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard progressive RT [control (CON)]
Number of subjects: 20
Study: 29169264

Group type: EXPERIMENTAL
Intervention: Mating condition (faces encoded in the context of long-term mating relationship)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Working condition (faces encoded in the context of long-term work relationship)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mating condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Working condition
Number of subjects: 0
Study: 25607523

Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 11

Group type: COMPARATOR
Intervention: P-TENS
Number of subjects: 11
Study: 23511090

Group type: EXPERIMENTAL
Intervention: Primary care-based intervention with 4 sessions conducted in the child's primary health care office.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control condition (details not specified).
Number of subjects: 60
Study: 22840253

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid medicine (only 45% of elementary school participants and 12% of high school participants)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Self-reported controller use
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: No reliever medicine in home
Number of subjects: 101
Study: 19938332

Group type: EXPERIMENTAL
Intervention: Oral functional training
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Tongue pressure and oral diadochokinesis (pronouncing 'ka')
Number of subjects: 48
Study: 17312208

Group type: EXPERIMENTAL
Intervention: Sugammadex 0.5 mg/kg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sugammadex 1.0 mg/kg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sugammadex 2.0 mg/kg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sugammadex 4.0 mg/kg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sugammadex 8.0 mg/kg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Rocuronium 1.2 mg/kg
Number of subjects: 50
Study: 15351752

Group type: EXPERIMENTAL
Intervention: Routine influenza vaccination (injected or intranasal spray)
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Injectable vaccine for infants (6 months to 35 months)
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Potential barriers to implementation
Number of subjects: 458
Study: 12683227

Group type: EXPERIMENTAL
Intervention: One boiled egg per day for 8 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Egg-free period
Number of subjects: 18
Study: 10414674

Group type: EXPERIMENTAL
Intervention: Ketoprofen, 100 mg, three times a day
Number of subjects: 18

Group type: COMPARATOR
Intervention: Acetaminophen, 1 g, three times a day
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 18
Study: 8649915

Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg dexamethasone syrup
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg dexamethasone syrup
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg dexamethasone syrup
Number of subjects: 120
Study: 2180259

Group type: EXPERIMENTAL
Intervention: Low dose bromocriptine
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Very low dose bromocriptine
Number of subjects: 64

Group type: COMPARATOR
Intervention: Higher dosage regimen of bromocriptine
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Maintenance dosage of bromocriptine (5 mg-15 mg daily)
Number of subjects: 64
Study: 218296

Group type: EXPERIMENTAL
Intervention: Sodium heparin
Number of subjects: 112

Group type: COMPARATOR
Intervention: Calciparine
Number of subjects: 112
Study: 31547771

Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 132
Study: 29080466

Group type: EXPERIMENTAL
Intervention: Exercise group (n=12), attended three exercise sessions per week for 8 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Non-exercise control group (n=12), advised to continue usual activities
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Exercise group (n=12)
Number of subjects: 24
Study: 25586468

Group type: EXPERIMENTAL
Intervention: Rindopepimut and standard adjuvant temozolomide chemotherapy
Number of subjects: 65
Study: 23533460

Group type: EXPERIMENTAL
Intervention: D&G herbal capsules 1 gm/day
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: D&G herbal capsules 2 gm/day
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 90
Study: 21942183

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 80

Group type: COMPARATOR
Intervention: Medication (Glibenclamide 2.5‐7.5 mg/time, 1‐2 times/d for 12 weeks)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Comparison between Acupuncture and Medication
Number of subjects: 80
Study: 19826060

Group type: EXPERIMENTAL
Intervention: dexlansoprazole MR 90 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: dexlansoprazole MR 300 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: moxifloxacin 400 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study: 16717144

Group type: EXPERIMENTAL
Intervention: Reboxetine (8 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 14762784

Group type: EXPERIMENTAL
Intervention: Polytetrafluoroethylene‐covered stent (group 1; 39 patients)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual uncovered prosthesis (group 2; 41 patients)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Polytetrafluoroethylene‐covered stent (group 1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual uncovered prosthesis (group 2)
Number of subjects: 80
Study: 14562531

Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 64

Group type: COMPARATOR
Intervention: Silverex
Number of subjects: 64
Study: 9701429

Group type: EXPERIMENTAL
Intervention: flutter
Number of subjects: 22

Group type: COMPARATOR
Intervention: PEP mask
Number of subjects: 22
Study: 7829780

Group type: EXPERIMENTAL
Intervention: Dobutamine (5 micrograms/kg body weight per min, n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: MS-857 (15 mg, n = 10)
Number of subjects: 20
Study: 2194417

Group type: EXPERIMENTAL
Intervention: Oral antibiotics (neomycin and erythromycin)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Intravenous cefoxitin
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Combination of oral and intravenous antibiotics
Number of subjects: 169

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 169
Study: 369735

Group type: EXPERIMENTAL
Intervention: Flunisolide nasal spray (0.025% solution, 200 microgram daily dosage)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (inactive aqueous vehicle)
Number of subjects: 50
Study: 31485869

Group type: EXPERIMENTAL
Intervention: Extra-infarct volume increase
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Extra-penumbra volume increase
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Absence of recanalization
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Progression to infarct at 7 days
Number of subjects: 132
Study: 29043911

Group type: EXPERIMENTAL
Intervention: Low dose of alcohol
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control beverage (no alcohol)
Number of subjects: 50
Study: 27449273

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 24507118

Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Program for Schizophrenia (RECOS), 14 weeks duration
Number of subjects: 16

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU), no intervention
Number of subjects: 16
Study: 22119855

Group type: EXPERIMENTAL
Intervention: Self-expanding CoreValve prosthesis
Number of subjects: 181
Study: 20801500

Group type: EXPERIMENTAL
Intervention: Ivabradine (titrated to a maximum of 7.5 mg twice daily)
Number of subjects: 6558

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6558

Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 6558
Study: 19100377

Group type: EXPERIMENTAL
Intervention: Celsior solution (CS)
Number of subjects: 88

Group type: COMPARATOR
Intervention: University of Wisconsin (UW)
Number of subjects: 88
Study: 15664719

Group type: EXPERIMENTAL
Intervention: Active 12-step participation
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Increased 12-step participation during the first 3 months of treatment
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Individual Drug Counseling based on a 12-step model
Number of subjects: 487

Group type: COMPARATOR
Intervention: Twelve-step group attendance
Number of subjects: 487
Study: 12228945

Group type: EXPERIMENTAL
Intervention: Return to work after musculoskeletal injury
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Health-related quality of life measures
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Reinjury rates
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Functional limitations
Number of subjects: 205
Study: 10579471

Group type: EXPERIMENTAL
Intervention: 200 mL double-strength grapefruit juice
Number of subjects: 10

Group type: COMPARATOR
Intervention: water (control)
Number of subjects: 10
Study: 8636369

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg, twice daily)
Number of subjects: 9
Study: 1751081

Group type: EXPERIMENTAL
Intervention: Na+ modeling (Na+ = 149 meq/L)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard Na+ dialysate (Na+ = 140 meq/L)
Number of subjects: 39
Study: 6749875

Group type: EXPERIMENTAL
Intervention: Progressive relaxation (PR) exercises via a 30-min self-instructional color videotape.
Number of subjects: 61

Group type: COMPARATOR
Intervention: Neutral videotape (control group).
Number of subjects: 61
Study: 30850677

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 102
Study: 28951059

Group type: EXPERIMENTAL
Intervention: Nutrition education during 1 90-minute grocery store tour
Number of subjects: 132
Study: 27440634

Group type: EXPERIMENTAL
Intervention: SAX‐IP approach (short‐axis in‐plane)
Number of subjects: 40

Group type: COMPARATOR
Intervention: SAX‐OOP approach (short‐axis out‐of‐plane)
Number of subjects: 40
Study: 24869973

Group type: EXPERIMENTAL
Intervention: PLD (30 mg/m(2)) and trabectedin (1.1 mg/m(2)) in overweight and obese patients (n = 48)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: PLD (30 mg/m(2)) and trabectedin (1.1 mg/m(2)) in normal weight patients (n = 26)
Number of subjects: 74
Study: 22118291

Group type: EXPERIMENTAL
Intervention: Preference arm (medical vs surgical termination of pregnancy)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Random arm (medical vs surgical termination of pregnancy)
Number of subjects: 30
Study: 20951309

Group type: EXPERIMENTAL
Intervention: Single-file F2 ProTaper technique in reciprocating motion (group 2)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Full range of ProTaper Universal instruments in rotary motion (group 1)
Number of subjects: 54
Study: 17331750

Group type: EXPERIMENTAL
Intervention: High-risk screening for AAA
Number of subjects: 12639

Group type: EXPERIMENTAL
Intervention: Low-risk screening for AAA
Number of subjects: 12639

Group type: COMPARATOR
Intervention: High-risk screening
Number of subjects: 12639
Study: 16260982

Group type: EXPERIMENTAL
Intervention: Running at 95% IAT
Number of subjects: 14

Group type: COMPARATOR
Intervention: Running at 70% IAT
Number of subjects: 14
Study: 12117660

Group type: EXPERIMENTAL
Intervention: Fluticasone 50 microg b.i.d. only (group F)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Combined SCG (2 mg four times daily) and fluticasone propionate powder 50 microg b.i.d. (group FS)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Combined SCG and fluticasone (group FS)
Number of subjects: 104
Study: 10672387

Group type: EXPERIMENTAL
Intervention: EMLA cream applied over skin areas corresponding to injection sites one hour before nerve blocks, placebo intravenous normal-saline injection 2 minutes before the first nerve block.
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Intravenous alfentanil 10 micrograms.kg‐1, placebo cream applied.
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo cream and intravenous normal-saline at similar time intervals prior to the nerve blocks.
Number of subjects: 75